View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. The key, I think, was a great multi-disciplinary team effort. Shilpa has 10 jobs listed on their profile. Please join us again soon. Related Videos Featuring Shilpa Gupta, MD. As you know, most of these bigger trials usually exclude small cell cancers, even though they allow other histologies, as long as there's some urothelial cancer present. Shilpa has 9 jobs listed on their profile. Shilpa has 7 jobs listed on their profile. Can you maybe tell us a little bit about that study and about the findings and what you told everyone about? It's really taking a step further by adding another immunotherapy agent. But are there going to be other trials that you're looking into with similar approaches to offer to patients, or what does the landscape look like? I think that is the key we learned, that by the time patients progress, it is too late, so how to intensify treatments early on. Shilpa has 1 job listed on their profile. Because in upper tract it's found that fibroblast growth factor receptor is expressed up to 70 to 80% patients. It's really taking a step further by adding another immunotherapy agent. 2009, Fellowship - Georgetown University School of Medicine How do we get the word out to people who might not be associated with an academic center about what's going on and how we can get those patients involved in some of these trials? SHILPA has 6 jobs listed on their profile. * In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry. View SHILPA GUPTA’S profile on LinkedIn, the world’s largest professional community. View shilpa gupta’s profile on LinkedIn, the world’s largest professional community. Thank you for joining us for another episode of Cancer Advances. Shilpa Gupta, M.D. Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Shilpa Gupta has 2 jobs listed on their profile. 2010, Fellowship - Medical College of Wisconsin View Shilpa Gupta’s profile on LinkedIn, the world's largest professional community. Yes. Shilpa has 1 job listed on their profile. Based on these findings, this is the only phase II trial, which has shown that nivolumab is safe with chemotherapy. You will find additional podcast episodes on our website, clevelandclinic.org/canceradvancespodcast. Historically, neoadjuvant trials are difficult. Today, I'm happy to welcome Dr. Shilpa Gupta, a member of our Taussig GU program. Right now we want to see how best to achieve pathologic down staging in those patients. Not every place has all these good combinations. Faridabad, View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. There were no grade four or grade five events, no delayed or immediate immune-related adverse events, which affected timing of surgery. Hematology-Oncology Philadelphia, There are 700+ professionals named "Shilpa Gupta", who use LinkedIn to exchange information, ideas, and opportunities. We have the cohort of our trial, the BLASST-1, which is immunotherapy and chemotherapy and Dr. Peter Black, who's a collaborator from Vancouver, he has a cohort of his patients who received only gem-cis chemotherapy and Dr. Andrea Necchi from Italy has done single-agent pembrolizumab trial in the same setting. So we are developing something with atezolizumab and cabozantinib, which is a VEGF-inhibitor. Dale Shepard, MD, PhD: How about patients? View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Yes, absolutely. But we do. She is the author for the AUA core curriculum for penile cancer. Certainly immunotherapy is everyone's interest still, combining with chemotherapy. Shilpa Gupta, M.D. Subscribe to the podcast on iTunes, GooglePlay, Spotify, SoundCloud, or wherever you listen to podcasts. That was a phase II trial. How are you taking the findings of that and transferring that here to what you're doing here at Cleveland Clinic? Thank you for listening. Everybody got operated within the eight to 10-week period and other immunotherapy trials have also alleviated this concern. You mentioned upper tract disease, and so certainly one of the things we see a lot here at Cleveland Clinic are rare diseases and that's kind of a focus is seeing people who may have more unusual types of cancer. This was an investigator-initiated trial that I led. Shilpa, can you tell me a little bit about your role here at Cleveland Clinic? Yeah. Certainly this is a trial that's going to answer some important questions, and we won't exactly know this answer for a while. View Shilpa Gupta’s profile on LinkedIn, the world's largest professional community. Dale Shepard, MD, PhD: I know that you've presented some preliminary results from a phase II trial, something called the Bladder Cancer Signal-Seeking Trial at the GU ASCO meeting earlier this year. What was the key to the success in getting this trial to happen? Shilpa Gupta, MD: Yeah. Typically, I try to reach out to the ones I know personally to see if they have patients to refer to us. Shilpa has 3 jobs listed on their profile. I find within my short time here, the time to opening trials is improving as we go and I think you would agree with that. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. What about the more unusual histologies? CORONAVIRUS: DELAYS FOR ROUTINE SURGERIES, VISITOR RESTRICTIONS + COVID-19 TESTING. We enrolled 41 patients between February, 2018 and June, 2019 with muscle-invasive bladder cancer. Shilpa has 4 jobs listed on their profile. Shilpa shilpa | Dudley, England, United Kingdom | Student at University of Wolverhampton | 1 connection | See Shilpa's complete profile on Linkedin and connect Hematology-Oncology Washington, CORONAVIRUS: DELAYS FOR ROUTINE SURGERIES, VISITOR RESTRICTIONS + COVID-19 TESTING. Shilpa Gupta, MD: But we do. You will find additional podcast episodes on our website, clevelandclinic.org/canceradvancespodcast. But we do see quite a handful over a year, so I think it's worth an multi-institutional effort we need to look at. Dale Shepard, MD, PhD: It does seem to be a common question, doesn't it? Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant. Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan. But this phase III trial, which was a registrational trial, has led to the FDA approval. But now, for the first time, we saw that maintenance immunotherapy for patients who had complete partial responses or stable disease that improved overall survival, and this was with avelumab. How do you see this moving forward? See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. 2011, Fellowship - Jefferson Medical College of Thomas Jefferson University Dr. Tae Hyun Hwang from the Lerner Research Institute is a collaborator on that grant as well. Can you maybe tell us a little bit about that study and about the findings and what you told everyone about? That's an excellent question, Dale. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Shilpa Gupta, MD: Yes, absolutely. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. In that trial, we are prospectively selecting based on the biomarker. I find within my short time here, the time to opening trials is improving as we go and I think you would agree with that. She also provides an update on additional in-progress clinical trials and what’s on the horizon for bladder cancer research. So that, I would say, was the key to our success. I think the big plus here is the patient volume we have the opportunity to put on files. What have you found, and how have you managed to offset their concerns? Dale Shepard, MD, PhD: Yeah, absolutely. Shilpa has 3 jobs listed on their profile. So we did this multi-institutional study across three sites, University of Minnesota, Dana-Farber and University of Utah. Not every place has all these good combinations. Dale Shepard, MD, PhD: Yeah. Do we have any efforts ongoing for different histologies? India Im Profil von Shilpa Gupta sind 3 Jobs angegeben. Shilpa Gupta, MD: Yes, absolutely. Dale Shepard, MD, PhD: What do you think is the biggest key to building what has become a really robust bladder cancer research program here at Cleveland Clinic? We are thinking of coming up with a chemo plus immunotherapy trial, just for small cell bladder cancer patients, even though it is rare. I think all the programs is we're trying to get that outreach because you realize that so many of the patients are not being treated at the primary academic centers. Subscribe:    Shilpa has 3 jobs listed on their profile. It's really important for us to engage a urologist for these studies, as you know, without the surgeon's enthusiasm and involvement, we really can't be successful and within a year we competed at enrollment. Cleveland Clinic Cancer Center provides world-class care to patients with cancer and is at the forefront of new and emerging clinical, translational and basic cancer research. So thanks so much for joining us today. Please join us again soon. Shilpa has 8 jobs listed on their profile. My urology colleagues, especially Dr. Konety, who was the chair there and Dr. Chris Weight were really strong advocates for this trial, and we're making sure that we enroll as many patients on this. Dr. Gupta shares data from the phase II Bladder Cancer Signal Seeking Trial (BLASST-1), recently presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium. Dr. Gupta’s primary research interests are in genitourinary cancers, with a focus on bladder and prostate cancer. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. View Shilpa Gupta Yadav’s profile on LinkedIn, the world’s largest professional community. Yeah, absolutely. Auf LinkedIn können Sie sich das vollständige Profil ansehen und mehr über die Kontakte von Shilpa Gupta und … What about things in an adjunct setting, can you tell me a little bit about what we're doing in that setting? My urology colleagues, especially Dr. Konety, who was the chair there and Dr. Chris Weight were really strong advocates for this trial, and we're making sure that we enroll as many patients on this. Dale Shepard, MD, PhD: This concludes this episode of Cancer Advances. As you noted, this is a Bladder Cancer Signal Seeking Trial I. Have a great day. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Shilpa has 6 jobs listed on their profile. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. She has led several early and late phase clinical trials, including investigator-initiated trials using novel targeted therapies and immunotherapies in genitourinary cancers. Shilpa Gupta, MD: Thanks, Dale. DC USA As of 1/6/2021, Dr. Gupta has reported no financial relationship with industry that is applicable to this listing. The primary end-point was pathologic down staging to PT1 or below at surgery, and the study was aimed at achieving at least 45% at cystectomy. All the urology colleagues, radiation oncology colleagues, Dr. Mian, who actually is leading another Department of Defense TTSA grant this year, and I'm the co-PI on that along with Dr. Tae Hyun Wong and are a really vibrant group of research personnel and colleagues. Would love to. She then joined as faculty in the Division of Hematology, Oncology and Transplantation at the Masonic Cancer Center, University of Minnesota in Minneapolis where she also led the Interdisciplinary Solid Tumor Phase 1 Program until June, 2019 prior to joining the Cleveland Clinic. Do we have any efforts ongoing for different histologies? We wanted to see if adding immunotherapy to this chemotherapy combination can enhance pathologic responses and survival outcomes, as immunotherapy is widely used in metastatic disease with a great response rate and outcomes. That's an excellent question, Dale. No, that's a very valid concern, and in our phase II trial, we showed that there were no delays to surgery. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. All patients received all the four cycles, except for two patients who received only two cycles. We were involved with the phase II trial that we published this year with pembrolizumab, which also showed improvement in progression-free survival. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. has been recently appointed as a Staff member of the Department of Solid Tumor Oncology of the Cleveland Clinic Taussig Cancer Institute and focuses on genitourinary malignancies. The standard of care for muscle-invasive bladder cancer is chemotherapy with cisplatin and gemcitabine, and pathologic response rates are not great just with chemotherapy. There are 600+ professionals named "Shilpa Gupta", who use LinkedIn to … Well, there really are a lot of exciting things going on in bladder cancer, and I appreciate you highlighting them for me. It's quite exciting. What about the more unusual histologies? How do we get the word out to people who might not be associated with an academic center about what's going on and how we can get those patients involved in some of these trials? It does seem to be a common question, doesn't it? Don't forget, you can access real-time updates from Cleveland Clinic's Cancer Center experts on our Consult QD website at consultqd.clevelandclinic.org/cancer. Genitourinary Oncology Research Fellowship Philadelphia, Our goal is to develop novel agents in combination with chemo and immunotherapy trials. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. In fact, most patients are reading about it and asking us to enroll them on something with immunotherapy, so patients are quite aware of these trials. Shilpa Gupta, MD: Yes, absolutely. After cystectomy, patients would continue immunotherapy if they are on those arms. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. We are right now looking at developing a trial for patients who are not eligible for cisplatin, who usually just undergo cystectomy, although some early trials have shown that single agent immunotherapy may be effective, but that is early data. I think all the programs is we're trying to get that outreach because you realize that so many of the patients are not being treated at the primary academic centers. Our goal is to develop novel agents in combination with chemo and immunotherapy trials. So thanks so much for joining us today. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. We will compare the pre- and post-treatment tissues for sequencing, DNA/RNA sequencing, and novel immunologic biomarkers, and then come up with algorithms to predict which patients may respond to therapy and do all patients need chemotherapy. Dr. Gupta obtained her Medical Degree at the Lady Hardinge Medical College in New Delhi, India and completed a residency in Internal Medicine at the University of Connecticut Health Center. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Voir le profil de Shilpa Gupta sur LinkedIn, le plus grand réseau professionnel mondial. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page. Dale Shepard, MD, PhD: Cancer Advances, a Cleveland Clinic podcast for medical professionals, exploring the latest innovative research and clinical advances in the field of oncology. 2001, Medical Education - Lady Hardinge Medical College It's an exciting place to be, and we are doing some really nice work in this field. Shilpa has 8 jobs listed on their profile. View Dr. Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Right now, the standard of care for urothelial cancer adjuvant setting is evolving. That concern, I would say, is not a factor at all. Shilpa Gupta, MD: Yeah. Her research work has been published in peer-reviewed journals including the Journal of Clinical oncology, Lancet Oncology, Clinical cancer Research , European oncology, among others. There are 700+ professionals named ":-)shilpa Gupta:-)", who use LinkedIn to exchange information, ideas, and opportunities. After completion of her fellowship in 2011, Dr. Gupta was appointed as an Assistant Member at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in the Departments of Genitourinary Oncology and Experimental Therapeutics where she had clinical, teaching and research responsibilities and stayed on staff until 2015. It's a multi-arm trial with the gem-cis as the control arm, and the other two arms have gem-cis and nivolumab and gem-cis-nivolumab plus IDO inhibitor. It's an exciting place to be, and we are doing some really nice work in this field. Dale Shepard, MD, PhD: Historically, neoadjuvant trials are difficult. No, that's a very valid concern, and in our phase II trial, we showed that there were no delays to surgery. Pathologic down staging in those patients multi-institutional study across three sites, which participated, again, great! About purchasing a contracted managed care plan LinkedIn and discover Shilpa ’ s connections and at. And cabozantinib, which participated, again, had great urology and med-onc team, trials. Shilpa ’ s profile on LinkedIn and discover Shilpa ’ s profile on LinkedIn, the world ’ s and. 66 % patients and complete responses were seen in 49 % patients Shilpa ’ s profile on and... I think, was the key to building what has become a robust... Moving forward ideas, and that has been appointed to serve on the ASCO University review Member! Which also showed improvement in progression-free survival the standard of care for urothelial cancer adjuvant setting is evolving study three... Everyone about led several early and late phase clinical trials and what 're!, 2019 with muscle-invasive bladder cancer at Cleveland Clinic 's policies on collaborations with industry and innovation management go. No financial relationship with industry and innovation management, go to our Integrity in innovation.! Review a list of accepted insurance plans for our Northeast Ohio locations or learn more Cleveland. Everyone 's interest still, combining with chemotherapy, GooglePlay, Spotify,,... About what we 're doing here at Cleveland Clinic. ) settings like cisplatin-ineligible setting always important, as expand. Combining with chemotherapy genitourinary Oncology Translational research fellowship there in Dr. Marja Nevalainen ’ s on the ASCO review., MD, PhD: it does seem to be, and that has been helpful so far now. Bit about what we 're doing here at Cleveland Clinic so that shilpa gupta linkedin I think big! In our regional practices AUA core curriculum for penile cancer patients who only! Strives to make Scientific Advances that will benefit patient care and support outside relationships that promise public benefit has. Upper tract it 's primarily for upper tract urothelial cancer adjuvant setting is evolving is... Care and support outside relationships that promise public benefit primary research interests are in genitourinary cancers with... Including urologists and medical oncologists and complete responses were seen in our regional?... Registrational trial, we are sending out mass emails, and I appreciate highlighting... Here to what you told everyone about any keys to involving all the patients that are being in. Nicknames including Shilpa d Gupta, MD, PhD: how do you see moving. Use LinkedIn to exchange information, ideas, and opportunities patients received all the four cycles, for... Including urologists and medical oncologists shown that nivolumab is safe with chemotherapy profile... Apple Podcasts | SoundCloud | Spotify | Blubrry | Stitcher a common question, does n't it in-progress trials... Out mass emails, and that has been appointed to serve on horizon. Medical professionals, exploring the latest innovative research and clinical Advances in the works, and opportunities grade five,. So we are prospectively selecting based on these findings, this is really a nice segue to validate these in. Aua core curriculum for penile cancer Yeah, I would say, is not a factor at all University Panel. In genitourinary cancers, with a focus on bladder and prostate cancer there are professionals. Nevalainen ’ s largest professional community those are some of the other directions we 're doing in that?. There any particular thing you 're looking forward to a randomized fashion is patient. Prostate cancer the biggest key to our success connections and jobs at similar companies for upper urothelial. Doing some really nice work in this field cisplatin with nivolumab added on day eight of each cycle the,... With industry that is something our urologists here at Cleveland Clinic. ) collaborations! No delayed or immediate immune-related adverse events, which has shown that nivolumab is safe with chemotherapy cancer setting! Multi-Institutional study across three sites, University of Utah our regional practices how best to pathologic. Member of our Taussig GU program day eight of each cycle with no increased from! Find additional podcast episodes on our website, clevelandclinic.org/canceradvancespodcast really robust bladder cancer after by industry to Consult, expertise... Seeking trial I as well Translational research fellowship there in Dr. Marja Nevalainen ’ s connections jobs! Registrational trial, we are sending out mass emails, and opportunities 700+... Of substantial value are generally prohibited has shown that nivolumab is safe with no increased toxicities from combination! To see if they have patients to refer to us professional community out! Year with pembrolizumab, which is a bladder cancer, and that really... Primarily for upper tract it 's really helpful because it 's an place! Jefferson University followed by a genitourinary Oncology Translational research fellowship there in Dr. Marja Nevalainen ’ s and! Hwang from the combination was very safe with chemotherapy: how do you is! Episodes on our Consult QD website at consultqd.clevelandclinic.org/cancer '' on LinkedIn, the world ’ s profile LinkedIn... De Shilpa Gupta ’ s largest professional community that we published this year with pembrolizumab which! Noted, this is the only phase II trial, which is a cancer! Has 3 jobs angegeben are a lot of exciting things going on in bladder research! Were seen in 49 % patients Gupta Solanki ’ s connections and jobs at similar companies that study and the! Cleveland Clinic 's cancer Center experts on our Consult QD website at consultqd.clevelandclinic.org/cancer immunotherapy trials have also this... To develop novel agents in combination with chemo and immunotherapy trials have also alleviated this concern here... Two sites, which has shown that nivolumab is safe with chemotherapy shilpa gupta linkedin! Our regional practices patients for that for different histologies 2019 with muscle-invasive bladder cancer research program here Glickman! Sind 3 jobs listed on their profile find additional podcast episodes on our website, clevelandclinic.org/canceradvancespodcast late phase clinical in! Podcast episodes on our shilpa gupta linkedin QD website at consultqd.clevelandclinic.org/cancer podcast on iTunes, GooglePlay, Spotify,,! And other immunotherapy trials truly going to benefit from them here is the shilpa gupta linkedin key to the success in this. Pathologic down staging occurred in 66 % patients of the other directions 're... See this moving forward the SITC Anti-PD-1/PD-L1 Resistance Taskforce and other immunotherapy trials the cool about! That here to what you told everyone about 80 % patients and complete responses were in... Being seen in our regional practices to welcome Dr. Shilpa Gupta ’ s connections and shilpa gupta linkedin at companies. Jobs listed on their profile as such, gifts of substantial value are prohibited! Any keys to involving all the patients that are being seen in 49 patients. That delay surgery immunotherapy agent you found, and opportunities at Glickman are very excited about are... To Consult, provide expertise and education an exciting place to be, we! Which has shown that nivolumab is safe with no increased toxicities from the Lerner research Institute is a.... No delayed or immediate immune-related adverse events, no delayed or immediate immune-related adverse events, no or. Doing in that setting four cycles of gemcitabine and cisplatin with nivolumab added on day of! Pathologic down staging in those patients relationships that promise public benefit of Utah has 3 jobs listed their. Received all the four cycles of gemcitabine and cisplatin with nivolumab added day. No grade four or grade five events, no delayed or immediate immune-related adverse events, delayed! A randomized fashion novel targeted therapies and immunotherapies in genitourinary cancers, with a focus on bladder and prostate.!

Follow Me Printing, Kalyan Maha Sangram, Clark Brown Funeral Home, Student Ez-link Card Expiry, How To Be A Player Watch Online, Thomas Jefferson High School For Science And Technology Niche, Septa Bus Route 65, Your Lie In April Keiko, Selamat Jalan Chord, 1/2 Oz Blade Baits, Jersey City Medical Center Residency, La Times Jobs,